Literature DB >> 22621876

Pathologic lymph node ratio is a predictor of survival in esophageal cancer.

Castigliano M Bhamidipati1, George J Stukenborg, Christopher J Thomas, Christine L Lau, Benjamin D Kozower, David R Jones.   

Abstract

BACKGROUND: A ratio between pathologic and examined lymph nodes may have predictive relevance in esophageal cancer. We sought to determine the prognostic value of lymph node ratio (LNR) compared with TNM and N stage using the seventh edition American Joint Commission on Cancer and International Union Against Cancer criteria.
METHODS: We abstracted data from 347 consecutive patients undergoing esophagectomy for esophageal cancer between 1999 and 2010 at our institution. Patients were stratified into surgery alone or induction therapy followed by surgery. Kaplan-Meier and Cox proportional hazard models estimated the survival function using LNR as a continuous variable or categorized into 0, more than 0.0 to less than 0.1, 0.1 to less than 0.2, 0.2 to less than 0.3, and 0.3 or greater. The influence of LNR on survival was assessed by the Wald χ(2) statistic and survival plots.
RESULTS: A total of 173 patients (49.9%) underwent induction therapy. The pathologic complete response rate was 55 of 173 (32%). The median number of examined nodes in surgery alone was 14 (interquartile range, 8 to 21), and induction was 12 (interquartile range, 7 to 17). Patients with nodal disease (n = 137) had a median LNR of 0.2 with equivalent survival regardless of induction therapy. Examination of LNR as a continuous variable demonstrated that LNR is an independent predictor of survival in both groups. After categorization, LNR contributed more toward estimating survival than pN stage in both groups.
CONCLUSIONS: Lymph node ratio is an independent predictor of survival in patients undergoing esophagectomy for esophageal cancer. The LNR makes a greater contribution in estimating overall survival than pN stage, regardless of the utilization of induction therapy.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22621876     DOI: 10.1016/j.athoracsur.2012.03.078

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  19 in total

1.  Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma.

Authors:  Arianna Barbetta; Francisco Schlottmann; Tamar Nobel; David B Sewell; Meier Hsu; Kay See Tan; Hans Gerdes; Pari Shah; Manjit S Bains; Matthew Bott; James M Isbell; David R Jones; Daniela Molena
Journal:  Ann Thorac Surg       Date:  2018-04-05       Impact factor: 4.330

2.  Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy.

Authors:  Danica N Giugliano; Adam C Berger; Michael J Pucci; Ernest L Rosato; Nathaniel R Evans; Hanna Meidl; Casey Lamb; Daniel Levine; Francesco Palazzo
Journal:  J Gastrointest Surg       Date:  2017-06-29       Impact factor: 3.452

3.  Prognostic value of the number of lymph nodes resected in patients with lymph-node-negative esophageal squamous cell carcinoma.

Authors:  Guoping Xu; Ming Jin; Yingjie Shao; Yuan Chen; Zhonghua Ning
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

Review 4.  Endoscopic Treatment of High-Grade Dysplasia and Early Esophageal Cancer.

Authors:  Francisco Schlottmann; Marco G Patti; Nicholas J Shaheen
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

5.  Lymph node ratio-based staging system for esophageal squamous cell carcinoma.

Authors:  Shao-Bin Chen; Hong-Rui Weng; Geng Wang; Xiao-Fang Zou; Di-Tian Liu; Yu-Ping Chen; Hao Zhang
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

6.  The Lymph Node Ratio Is an Independent Prognostic Factor in Esophageal Cancer Patients Who Receive Curative Surgery.

Authors:  Norio Yukawa; Toru Aoyama; Hiroshi Tamagawa; Ayako Tamagawa; Yosuke Atsumi; Shinnosuke Kawahara; Yukio Maezawa; Kazuki Kano; Masaaki Murakawa; Keisuke Kazama; Masakatsu Numata; Takashi Oshima; Munetaka Masuda; Yasushi Rino
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

7.  Identification of the Lymphatic Drainage Pattern of Esophageal Cancer with Near-Infrared Fluorescent Imaging.

Authors:  Francisco Schlottmann; Arianna Barbetta; Benedetto Mungo; Anne O Lidor; Daniela Molena
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2016-12-19       Impact factor: 1.878

8.  Esophagectomy Following Endoscopic Resection of Submucosal Esophageal Cancer: a Highly Curative Procedure Even with Nodal Metastases.

Authors:  Daniela Molena; Francisco Schlottmann; Joshua A Boys; Shanda H Blackmon; Karen J Dickinson; Christy M Dunst; Wayne L Hofstetter; Michal J Lada; Brian E Louie; Benedetto Mungo; Thomas J Watson; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2016-08-25       Impact factor: 3.452

Review 9.  Lymph node dissection for esophageal cancer.

Authors:  Yasunori Akutsu; Hisahiro Matsubara
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-03-26

10.  Current treatment options for the management of esophageal cancer.

Authors:  Mark R Mawhinney; Robert E Glasgow
Journal:  Cancer Manag Res       Date:  2012-11-02       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.